BridgeMD
How does the response to measles-mumps-rubella vaccine at 6 months of age impact longevity of vaccine responses to subsequent MMR vaccines?
EU CTIS ID: 2026-526160-21-00
What this study is testing
The follow-up study has one primary aim: To measure the level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test 1-3 years after routine MMR vaccination at 4 years of age and compare this level between the two original MMR groups: The one, which received an early MMR and the one, which received placebo in the trial .
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participation in the original MMR trial
You likely can't join if
- Immune-deficiency (primary or acquired) or –suppression, and/or intake of immune modulating medicine (including high doses of corticosteroids), thrombocytopenia or any coagulation disorder, blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems. Children who received blood or plasma transfusions, or administration of human immune serum globulin within the last 3 months will be excluded.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.